Kazia Therapeutics Limited

NASDAQ (USD): Kazia Therapeutics Limited (KZIA)

Last Price

0.901

Today's Change

-0.339 (27.33%)

Day's Change

0.861 - 1.10

Trading Volume

17,348,035

Overview

Market Cap

11 Million

Shares Outstanding

12 Million

Avg Volume

11,255,000

Avg Price (50 Days)

0.28

Avg Price (200 Days)

0.42

PE Ratio

-2.37

EPS

-0.38

Earnings Announcement

29-Aug-2024

Previous Close

1.24

Open

1.07

Day's Range

0.8611 - 1.105

Year Range

0.19 - 1.58

Trading Volume

17,366,800

Price Change Highlight

1 Day Change

-27.35%

5 Day Change

328.54%

1 Month Change

260.46%

3 Month Change

153.03%

6 Month Change

157.44%

Ytd Change

100.18%

1 Year Change

-7.13%

3 Year Change

-90.66%

5 Year Change

-68.39%

10 Year Change

-93.34%

Max Change

-98.29%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment